Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析

◆英語タイトル:Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH57970FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Hikma Pharmaceuticals Plc (HIK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and rest of the world. Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc Key Recent Developments

Feb 25,2021: Hikma delivers strong performance in 2020
Feb 18,2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation and the National Children’s Cancer Society
Nov 30,2020: Amarin files patent infringement lawsuit against Hikma
Nov 05,2020: Hikma Pharmaceuticals – Board and committee changes
Nov 05,2020: Hikma continues strong 2020 performance and updates full year guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Hikma Pharmaceuticals Plc – Key Facts
Hikma Pharmaceuticals Plc – Key Employees
Hikma Pharmaceuticals Plc – Key Employee Biographies
Hikma Pharmaceuticals Plc – Major Products and Services
Hikma Pharmaceuticals Plc – History
Hikma Pharmaceuticals Plc – Company Statement
Hikma Pharmaceuticals Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Hikma Pharmaceuticals Plc – Business Description
Business Segment: Branded
Overview
Performance
Business Segment: Generics
Overview
Performance
Business Segment: Injectables
Overview
Performance
Business Segment: Others
Performance
Geographical Segment: Europe and Rest of the World
Performance
Geographical Segment: MENA
Performance
Geographical Segment: United Kingdom
Performance
Geographical Segment: United States
Performance
Hikma Pharmaceuticals Plc – Corporate Strategy
Hikma Pharmaceuticals Plc – SWOT Analysis
SWOT Analysis – Overview
Hikma Pharmaceuticals Plc – Strengths
Hikma Pharmaceuticals Plc – Weaknesses
Hikma Pharmaceuticals Plc – Opportunities
Hikma Pharmaceuticals Plc – Threats
Hikma Pharmaceuticals Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 25, 2021: Hikma delivers strong performance in 2020
Feb 18, 2021: Hikma donates over $4 million USD in medicines and signs new long-term partnerships with Dispensary of Hope, Direct Relief, Americares, Brother’s Brother Foundation and the National Children’s Cancer Society
Nov 30, 2020: Amarin files patent infringement lawsuit against Hikma
Nov 05, 2020: Hikma Pharmaceuticals – Board and committee changes
Nov 05, 2020: Hikma continues strong 2020 performance and updates full year guidance
Oct 20, 2020: Hikma and Arecor expand collaboration
Aug 18, 2020: DoseID launches to expand RFID interoperability and performance in healthcare
Aug 07, 2020: Hikma Pharmaceuticals : Half-year Report
Aug 07, 2020: Hikma delivers strong first half performance and raises full year guidance
Jun 25, 2020: Jochen Gann resigns from the Board of Hikma
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont...2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Hikma Pharmaceuticals Plc (HIK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pioneer Natural Resources Co (PXD)-石油・ガス分野:企業M&A・提携分析
    Summary Pioneer Natural Resources Company (Pioneer) is an independent oil and natural gas exploration and production company. Its principally operates in Eagle Ford Shale, Permian Basin, Raton Basin, and West Panhandle. In Permian Basin, the company carries out its exploration and production activit …
  • Engie Brasil Energia SA (EGIE3):電力:M&Aディール及び事業提携情報
    Summary Engie Brasil Energia SA (Engie Brasil), formerly Tractebel Energia SA, a subsidiary of Engie SA, undertakes the generation and commercialization of electricity. It generates energy through various source of energy such as hydro; thermal; and complementary energy sources including wind, solar …
  • Real Goods Solar Inc (RGSE):電力:M&Aディール及び事業提携情報
    Summary Real Goods Solar Inc (Real Goods Solar), doing business as RGS Energy, a subsidiary of Gaia Inc is a renewable energy company that offers solar energy products and solutions. The company's services include solar PV system designing, installation, consultation, maintenance, rebate acquisition …
  • Allianz Group:企業のM&A・事業提携・投資動向
    Allianz Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allianz Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Canada Energy Partners Inc (CE):石油・ガス:M&Aディール及び事業提携情報
    Summary Canada Energy Partners Inc (Canada Energy) is a natural gas exploration and development company. The company concentrates on mid-stream supplying of water disposal services, development of a wellbore mining technology and energy or mineral exploring. It develops a wellbore mining technology …
  • UCB SA (UCB):企業の財務・戦略的SWOT分析
    UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • TIBCO Software Inc:企業の戦略的SWOT分析
    TIBCO Software Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Southern Copper Corporation:企業の戦略・SWOT・財務情報
    Southern Copper Corporation - Strategy, SWOT and Corporate Finance Report Summary Southern Copper Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Famous Dave’s of America, Inc.:戦略・SWOT・企業財務分析
    Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Millennium Minerals Limited:企業の戦略・SWOT・財務情報
    Millennium Minerals Limited - Strategy, SWOT and Corporate Finance Report Summary Millennium Minerals Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Cara Therapeutics Inc (CARA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • Arthrex Inc-医療機器分野:企業M&A・提携分析
    Summary Arthrex Inc (Arthrex), formerly, Arthroscopy Excision Instruments Inc., is a medical device company which designs, and manufactures surgical products and solutions used for arthroscopic and minimally invasive orthopedic surgical procedures. The company offers shoulder, knee, elbow, hand and …
  • American Bio Medica Corp (ABMC):企業の製品パイプライン分析2018
    Summary American Bio Medica Corp (ABMC) is a biotechnology company that develops, manufactures and markets immunoassay test kits. The company’s products include Rapid TOX, a point of collection testing product that detects 1-10 drugs of abuse in a urine specimen; Rapid One, a test cassette which is …
  • Realord Group Holdings Limited:企業の戦略・SWOT・財務情報
    Realord Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Realord Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • JFE Holdings, Inc. (5411):企業の財務・戦略的SWOT分析
    JFE Holdings, Inc. (5411) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Gecko Biomedical:企業の製品パイプライン分析2018
    Summary Gecko Biomedical (Gecko) is a life science company that provides polymer solutions for tissue reconstruction. The company offers a platform that validates the technology in surgical spaces, including peripheral nerve reconstruction, ophthalmology, urology, and orthopaedics. It also provides …
  • Gadeta BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Gadeta BV (Gadeta) is a biotechnology company, which focuses on the research and development of cellular immunotherapies for the elimination of cancer. The company’s technology platform combines alpha beta T cells engineered to express defined Gamma Delta T cell receptors (TEGs) that demonst …
  • VSB Holding GmbH-エネルギー分野:企業M&A・提携分析
    Summary VSB Holding GmbH (VSB), formerly WSB Neue Energien GmbH is a renewable energy company that offers solutions for renewable energy projects. The company offers services such as wind energy services, photovoltaics services, investments and wind park management. It provides wind energy services …
  • California Resources Corp (CRC):企業の財務・戦略的SWOT分析
    California Resources Corp (CRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Nippon Life Insurance Company:企業の戦略・SWOT・財務情報
    Nippon Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Nippon Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆